REVIEW ON: ANTIRETROVIRAL DOLUTEGRAVIR DRUG
Dr. Sonali P. Mahaparale* and Jayraj U. Deshmukh
ABSTRACT
Dolutegravir is that the newest integrase strand transfer inhibitor which is granted for the treatment of human immunodeficiency virus (HIV) infection. Dolutegravir is identical or preferred to existing treatment regimens in both patients i.e. treatment-naïve and experienced patients including those with previous raltegravir or elvitegravir failure. Dolutegravir exhibits rapid absorption, with a median time to the utmost plasma concentration (tmax) starting from 0.5 to 2 h. Switching to a two-drug regimen of dolutegravir plus rilpivirine was also related to high rates of virological suppression in real-world observational studies. Dolutegravir make the co-formulation with the two-nucleotide reverse -transcriptase inhibitors as a best treatment option because it has a consistent efficacy which include the excellent tolerability and infrequent drug - drug interaction. Thus, dolutegravir gives a favourable alternative treatment option for a few adults with HIV-1 infection and no history of virological failure who are already virologic ally suppressed on (and wish to modify from) their current ART regimen. This review gives an overview of the pharmacokinetics, adverse event profile, and efficacy of dolutegravir within the treatment of HIV.
Keywords: Integrase inhibitor, antiretroviral therapy, drug-drug interaction, strand transfer step.
[Full Text Article]
[Download Certificate]
Impact Factor : 8.181 
